Chardan Sees Over 200% Upside On This Small-Cap Cancer-Focused Stock

  • Chardan has initiated coverage on Oncorus Inc ONCR with a Buy rating and a price target of $5.
  • The analysts based it on the company's commercial potential with its lead oncolytic virus immunotherapy ONCR-177 from its HSV platform.
  • Oncorus' HSV platform utilizes the herpes simplex virus (HSV) type 1 backbone that incorporates more transgenes, retains the ability to replicate in tumor cells, and has orthogonal safety strategies to attenuate viral replication in healthy tissues. 
  • Related: Why Did Oncorus Shares Slump To 52-Week Low Today?
  • The company's lead program, ONCR-177, is being evaluated as a monotherapy and combined with Merck & Co Inc's MRK Keytruda in an ongoing phase I study for solid tumors. 
  • Chardan notes that treatment in the monotherapy arm was "well tolerated with no dose-limiting toxicities," and the recommended phase 2 dose was determined as 4e8 PFU/dose in 4 mL.
  • The analyst projects an initial product launch for the program in 2026. Using a probability of success of 25% for the program, Chardan estimates ONCR-177 netting ~$230 million in probability-adjusted global sales in 2030.
  • Price Action: ONCR shares are down 3.40% at $1.57 during the market session on the last check Wednesday.

Posted In: BriefsAnalyst ColorBiotechNewsPenny StocksHealth CareInitiationAnalyst RatingsGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.